Abstract：
Despite advancements in short-term outcomes since the inception of intestinal transplant, significant long-term graft failure persists. Early successes are attributed to the utilization of tacrolimus for maintenance therapy, coupled with T-cell modulating induction regimens, which effectively reduce the incidence of acute cellular rejection. However, the challenge of chronic allograft injury remains unresolved. There is increasing evidence indicating a correlation between donor-specific antibodies and the survival of visceral allografts. Strategies aimed at reducing the presence or load of these antibodies may potentially enhance long-term outcomes. Consequently, our focus is now turning toward B-cell induction therapies as a possible solution.
摘要：
尽管自肠道移植开始以来，短期结果有所改善，显著的长期移植物失败持续存在。早期的成功归因于他克莫司用于维持治疗，加上T细胞调节诱导方案，从而有效降低急性细胞排斥反应的发生率。然而,慢性同种异体移植损伤的挑战仍未解决。越来越多的证据表明供体特异性抗体与内脏同种异体移植物的存活之间存在相关性。旨在减少这些抗体的存在或负荷的策略可能潜在地增强长期结果。因此,我们现在的重点是将B细胞诱导疗法作为一种可能的解决方案.
